Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insider Analysis From Sidley Austin LLP: Getting Ready For China’s Anti-Monopoly Law

This article was originally published in PharmAsia News

Executive Summary

By Chen Yang, Sidley Austin Beijing; and Adrian Emch, Sidley Austin Brussels

You may also be interested in...



Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition

With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.

Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition

With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.

China's MOFCOM Promises Increased Scrutiny Over M&A In 2012

China Ministry of Commerce announcement of increased M&A scrutiny, sends companies scrambling to submit papers in fear of bureaucratic delays.

Related Content

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel